Aigen Investment Management LP Invests $297,000 in Syndax Pharmaceuticals, Inc. $SNDX

Key Points

• Aigen Investment Management LP has purchased 24,158 shares of Syndax Pharmaceuticals, valued at approximately $297,000, as part of their investment strategy in the 1st quarter.
• Several institutional investors have increased their stakes in Syndax Pharmaceuticals, with Virtus ETF Advisers LLC lifting its holdings by 18.6% in the fourth quarter.
• Syndax Pharmaceuticals has received mixed ratings from analysts, with a consensus price target of $36.91, indicating a "Moderate Buy" sentiment among market experts.

Aigen Investment Management LP bought a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 24,158 shares of the company's stock, valued at approximately $297,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Virtus ETF Advisers LLC grew its holdings in shares of Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Syndax Pharmaceuticals by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company's stock valued at $706,000 after acquiring an additional 1,811 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Syndax Pharmaceuticals by 6.2% in the fourth quarter. MetLife Investment Management LLC now owns 50,515 shares of the company's stock valued at $668,000 after acquiring an additional 2,961 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Syndax Pharmaceuticals by 2.5% in the first quarter. Bank of New York Mellon Corp now owns 229,758 shares of the company's stock valued at $2,823,000 after purchasing an additional 5,497 shares during the period. Finally, ProShare Advisors LLC grew its stake in Syndax Pharmaceuticals by 32.2% during the 4th quarter. ProShare Advisors LLC now owns 27,183 shares of the company's stock worth $359,000 after purchasing an additional 6,627 shares in the last quarter.

Analyst Upgrades and Downgrades

SNDX has been the topic of a number of analyst reports. Scotiabank increased their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. UBS Group cut their target price on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, July 15th. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. B. Riley upgraded shares of Syndax Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, August 6th. Finally, BTIG Research increased their price objective on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $38.00.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 7,534 shares of the firm's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total transaction of $69,990.86. Following the transaction, the chief executive officer directly owned 298,661 shares of the company's stock, valued at approximately $2,774,560.69. This trade represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.

Syndax Pharmaceuticals Stock Up 0.3%

NASDAQ:SNDX traded up $0.06 during midday trading on Monday, hitting $15.80. 907,740 shares of the company were exchanged, compared to its average volume of 2,250,682. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $22.50. The company has a market capitalization of $1.36 billion, a PE ratio of -4.07 and a beta of 0.74. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. The company has a fifty day simple moving average of $10.35 and a 200 day simple moving average of $11.86.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $0.18. The firm had revenue of $37.96 million during the quarter, compared to analysts' expectations of $26.64 million. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%. The business's revenue was up 984.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.80) EPS. As a group, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).